Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CLDX NYSE:EBS NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.29-1.0%$9.16$6.00▼$11.31$2.11B0.574.77 million shs4.17 million shsCLDXCelldex Therapeutics$30.73+0.5%$31.99$18.55▼$35.79$2.41B0.98724,510 shs582,927 shsEBSEmergent Biosolutions$8.49+1.4%$8.31$5.61▼$14.06$436.39M2.33718,463 shs986,645 shsJNJJohnson & Johnson$234.67+1.3%$234.02$149.04▼$251.71$564.11B0.277.58 million shs5.46 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-8.09%-5.37%+11.28%-17.68%CLDXCelldex Therapeutics0.00%-1.95%-8.41%+33.49%+54.04%EBSEmergent Biosolutions0.00%+6.66%+4.99%-22.48%+31.75%JNJJohnson & Johnson0.00%+3.47%+1.73%-3.14%+53.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$8.29-1.0%$9.16$6.00▼$11.31$2.11B0.574.77 million shs4.17 million shsCLDXCelldex Therapeutics$30.73+0.5%$31.99$18.55▼$35.79$2.41B0.98724,510 shs582,927 shsEBSEmergent Biosolutions$8.49+1.4%$8.31$5.61▼$14.06$436.39M2.33718,463 shs986,645 shsJNJJohnson & Johnson$234.67+1.3%$234.02$149.04▼$251.71$564.11B0.277.58 million shs5.46 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-8.09%-5.37%+11.28%-17.68%CLDXCelldex Therapeutics0.00%-1.95%-8.41%+33.49%+54.04%EBSEmergent Biosolutions0.00%+6.66%+4.99%-22.48%+31.75%JNJJohnson & Johnson0.00%+3.47%+1.73%-3.14%+53.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70149.70% UpsideCLDXCelldex Therapeutics 2.80Moderate Buy$49.7861.98% UpsideEBSEmergent Biosolutions 2.00Hold$12.0041.43% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.047.83% UpsideCurrent Analyst Ratings BreakdownLatest EBS, JNJ, BCRX, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026CLDXCelldex Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$38.00 ➝ $54.005/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/11/2026EBSEmergent Biosolutions Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/8/2026CLDXCelldex Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $48.005/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/6/2026BCRXBioCryst Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.004/27/2026EBSEmergent Biosolutions Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/20/2026CLDXCelldex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$874.84M2.41$1.24 per share6.70($2.18) per share-3.80CLDXCelldex Therapeutics$1.54M1,566.23N/AN/A$5.81 per share5.29EBSEmergent Biosolutions$742.90M0.59$3.67 per share2.31$10.13 per share0.84JNJJohnson & Johnson$94.19B6.00$14.14 per share16.60$33.73 per share6.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A25.91N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)CLDXCelldex Therapeutics-$258.76M-$4.26N/AN/AN/AN/A-50.72%-46.59%8/6/2026 (Estimated)EBSEmergent Biosolutions$52.60M-$0.28N/AN/AN/A-1.27%10.76%4.22%8/5/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6527.1318.652.2921.83%32.60%13.29%7/15/2026 (Estimated)Latest EBS, JNJ, BCRX, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CLDXCelldex Therapeutics-$1.1472-$1.18-$0.0328-$1.18$0.80 million$0.02 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million4/30/2026Q1 2026EBSEmergent Biosolutions-$0.25$0.21+$0.46$0.07$145.00 million$156.10 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion2/26/2026Q4 2025BCRXBioCryst Pharmaceuticals$0.07$1.12+$1.05$1.12$151.32 million$163.28 million2/26/2026Q4 2025EBSEmergent Biosolutions$0.11-$0.43-$0.54-$1.04$217.50 million$148.70 million2/25/2026Q4 2025CLDXCelldex Therapeutics-$1.00-$1.22-$0.22-$1.22$1.53 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.202.22%+5.25%60.12%64 YearsLatest EBS, JNJ, BCRX, and CLDX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A1.911.88CLDXCelldex TherapeuticsN/A8.928.92EBSEmergent Biosolutions1.104.292.08JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CLDXCelldex TherapeuticsN/AEBSEmergent Biosolutions78.40%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CLDXCelldex Therapeutics5.20%EBSEmergent Biosolutions6.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530254.16 million241.20 millionOptionableCLDXCelldex Therapeutics15078.49 million74.41 millionOptionableEBSEmergent Biosolutions2,42051.64 million48.55 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableEBS, JNJ, BCRX, and CLDX HeadlinesRecent News About These CompaniesJohnson And Johnson Faces Minnesota Talc Verdict As Valuation Discount Persists4 hours ago | finance.yahoo.comLife Cycle Investment Partners Ltd Buys New Shares in Johnson & Johnson $JNJMay 24 at 6:09 AM | marketbeat.comPathfinder Wealth Consulting Inc. Takes Position in Johnson & Johnson $JNJMay 24 at 6:00 AM | marketbeat.comLegato Capital Management LLC Sells 9,548 Shares of Johnson & Johnson $JNJMay 24 at 5:40 AM | marketbeat.comFirst National Trust Co Sells 5,212 Shares of Johnson & Johnson $JNJMay 24 at 4:18 AM | marketbeat.comJohnson & Johnson (JNJ) Announces Positive Clinical Study Results for OTTAVA Robotic Surgical SystemMay 23 at 6:12 PM | finance.yahoo.comThe Single Premium Immediate Annuity That Adds $3,800 a Month to a $1.2 Million Income Portfolio Without Touching a StockMay 23 at 1:05 PM | 247wallst.comQuitting at 59 and Bridging Eight Years to Social Security at 67? Here Is the $530,000 Income Portfolio I Would BuildMay 23 at 8:10 AM | 247wallst.comGuinness Asset Management LTD Decreases Position in Johnson & Johnson $JNJMay 23 at 7:03 AM | marketbeat.comGPS Wealth Strategies Group LLC Sells 6,516 Shares of Johnson & Johnson $JNJMay 23 at 7:03 AM | marketbeat.comLSV Asset Management Cuts Position in Johnson & Johnson $JNJMay 23 at 6:39 AM | marketbeat.comCumberland Partners Ltd Has $12.29 Million Position in Johnson & Johnson $JNJMay 23 at 4:25 AM | marketbeat.comAmericana Partners LLC Grows Stock Position in Johnson & Johnson $JNJMay 23 at 3:25 AM | marketbeat.comJohnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference SlateMay 22 at 9:11 PM | seekingalpha.comJohnson & Johnson (NYSE:JNJ) Shares Up 1.3% - Here's What HappenedMay 22 at 5:37 PM | marketbeat.comIBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s FindingsMay 22 at 11:56 AM | stocktwits.comSJ&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?May 22 at 11:56 AM | finance.yahoo.comJ&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?May 22 at 11:05 AM | zacks.comVestmark Advisory Solutions Inc. Acquires 50,304 Shares of Johnson & Johnson $JNJMay 22 at 7:53 AM | marketbeat.comThe Dividend Stocks That Can Replace a $65,000 Income and What They'll Cost YouMay 22 at 7:36 AM | 247wallst.comSix Boring Blue Chips Generate $54,000 a Year on $920,000 Without a Single 7 Percent Yield TrapMay 22 at 7:15 AM | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBS, JNJ, BCRX, and CLDX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$8.29 -0.08 (-0.96%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$8.41 +0.13 (+1.51%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Celldex Therapeutics NASDAQ:CLDX$30.73 +0.15 (+0.49%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.45 -0.28 (-0.90%) As of 05/22/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Emergent Biosolutions NYSE:EBS$8.48 +0.12 (+1.37%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$8.40 -0.09 (-1.06%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Johnson & Johnson NYSE:JNJ$234.67 +2.94 (+1.27%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$234.43 -0.25 (-0.10%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
